This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cabot (CBT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cabot (CBT) delivered earnings and revenue surprises of 2.91% and 2.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Cabot (CBT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Cabot (CBT) is likely to see year-over-year revenue growth in Q3.
Cabot (CBT) Shares Up 10% QTD: What's Driving the Stock?
by Zacks Equity Research
Strong Q2 earnings and upbeat outlook for Reinforcement Materials and Performance Chemicals segments have contributed to the gain in Cabot's (CBT) shares
Cabot and Nexeo Expand Deal for Distribution in Canada
by Zacks Equity Research
Cabot's (CBT) latest move is likely to deliver meaningful benefits to its customers in Canada.
Why Cabot (CBT) Stock Might be a Great Pick
by Zacks Equity Research
Cabot (CBT) could be an interesting play for investors as it is seeing solid earnings estimate revision in addition to having a robust industry rank.
Cabot (CBT) Up 12.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Cabot (CBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cabot (CBT) to Exhibit Activated Carbon Products at ACHEMA
by Zacks Equity Research
Cabot (CBT) is set to showcase Norit range from activated carbon families at ACHEMA 2018, Germany, that will assist in catalyst application.
Cabot to Boost Global Carbon Black Capacity on Strong Demand
by Zacks Equity Research
Cabot's (CBT) latest move will expand its global carbon black capacity by more than 300,000 metric tons.
Cabot (CBT) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Solid performance in Reinforcement Materials and Performance Chemicals segments drives Cabot's (CBT) results in Q2.
Chemical Stock Earnings Slated on May 7: CBT, IFF & RYAM
by Zacks Equity Research
Chemical companies are expected to continue to gain from strategic measures this earnings season.
Cabot (CBT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Cabot's (CBT) Q2 results are likely to benefit from continued momentum in the specialty applications and a favorable pricing environment amid higher fixed costs.
Cabot Inks Licensing Deal With Midwest Energy Emissions
by Zacks Equity Research
Cabot (CBT) inks deal with Midwest Energy Emissions, under which, it will leverage the latter's patented technologies to enhance its current portfolio of mercury removal solutions.
Cabot (CBT) Bolsters Specialty Compounds Business Globally
by Zacks Equity Research
Cabot (CBT) completes two expansion projects to increase manufacturing capacity to better serve global customers and grow in advanced polymeric materials.
Cabot to Supply New Activated Carbon for POETS Project
by Zacks Equity Research
Cabot's (CBT) Hydrodarco 4000 activated carbon being the most effective in removing PFOA has been selected by the NYSDEC to ensure safe drinking water for the residents of Town of Hoosick.
Zacks.com featured highlights include: United Natural, Western Digital, Conduent, ArcBest and Cabot
by Zacks Equity Research
Zacks.com featured highlights include: United Natural, Western Digital, Conduent, ArcBest and Cabot
Buy These 7 Low Price-to-Sales Stocks That Promise Growth
by Zacks Equity Research
A stock's price-to-sales ratio reflects how much investors are paying for each dollar of revenues generated by the company.
5 Stocks With Amazingly Low EV/EBITDA Ratios to Scoop Up
by Zacks Equity Research
We have screened value stocks based on EV/EBITDA ratio that offers a clearer picture of a company's valuation and earnings potential.
Monsanto (MON) Downgraded to Sell on Predominant Headwinds
by Zacks Equity Research
China's 25% tariffs (announced Apr 4) on agricultural products, like soybean, or headwinds, such as stiff industry rivalry, anticipated to dent Monsanto's (MON) profitability.
Monsanto Company (MON) Q2 Earnings Miss Estimates, Up Y/Y
by Zacks Equity Research
Monsanto's (MON) second-quarter fiscal 2018 earnings came in lower than the year-ago tally and missed the Zacks Consensus Estimate as well.
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Curtiss-Wright, Stepan, Mellanox Technologies and Cabot
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comtech Telecommunications, Curtiss-Wright, Stepan, Mellanox Technologies and Cabot
Should Value Investors Pick Cabot (CBT) Stock Now?
by Zacks Equity Research
Cabot (CBT) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
5 Top-Ranked U.S. Stocks to Gain From Trump's China Tariffs
by Nalak Das
The U.S. government imposed 25% tariffs targeting 1,300 Chinese imports for a total worth of $50 billion.
Companhia Siderurgica (SID) Posts Q4 Earnings, Sales Solid
by Zacks Equity Research
Companhia Siderurgica Nacional's (SID) fourth-quarter 2017 net earnings increase over the year-ago quarter's loss. Revenues increase 10.5% year over year on higher steel products and iron ore prices.
Here's Why You Should Add Univar (UNVR) to Your Portfolio
by Zacks Equity Research
Univar (UNVR) stands to gain from a strong demand for its services, solid overseas operations and meaningful acquisitions. Rewarding shareholders and making growth investments remain priorities.
Monsanto (MON) & Pairwise to Jointly Roll Out Agro Solutions
by Zacks Equity Research
Monsanto (MON) and agricultural start-up firm, Pairwise Plants, to jointly roll out breakthrough crop-yield enhancing solutions with gene-editing technology.